Help
1422 Article Views
Publication Date: 23 Jun 2011
Journal: Clinical Medicine Insights: Oncology
doi: 10.4137/CMO.S6416
The review is concise and covers a broad aspect of initial treatment of newly-diagnosed patients with chronic phase CML with tyrosine kinase inhibitors.
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation of FDA-approved ABL tyrosine kinase inhibitors, dasatinib and nilotinib, are more potent inhibitors of BCR-ABL1 kinase in vitro. Originally approved for the treatment of patients who were refractory to or intolerant of imatinib, dasatinib and nilotinib are now also FDA approved in the first-line setting. The choice of tyrosine kinase inhibitor (ie, standard or high dose imatinib, dasatinib, nilotinib) to use for initial therapy in chronic-phase CML (CML-CP) will not always be obvious. Therapy selection will depend on both clinical and molecular factors, which we will discuss in this review.
Recently we published a paper describing cloning of a new kinase gene, MLK4, in Genomics Insights. I was impressed by the prompt processing and speed of publication. The comments from the reviewers allowed me to improve the paper significantly. The reviews were scientifically deep and objective, which is very valuable because in many journals decisions to publish or not to publish are very unfair and subjective. I highly recommend that other researchers publish their papers in Genomics Insights.Dr Eugene R. Zabarovsky (Karolinska Institute, Stockholm, Sweden) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube